Kura Oncology, Inc.
NMS: KURALive Quote
📈 ZcoreAI Score
Our AI model analyzes Kura Oncology, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get KURA Z-Score →About Kura Oncology, Inc.
Healthcare
Biotechnology
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
📊 Fundamental Analysis
Kura Oncology, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported -67.8% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -94.8%, which indicates that capital utilization is currently under pressure.
At a current price of $8.67, KURA currently sits at the 46th percentile of its 52-week range (Range: $5.45 - $12.49).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$765.82M
Trailing P/E
--
Forward P/E
-3.55
Beta (5Y)
0.24
52W High
$12.49
52W Low
$5.45
Avg Volume
1.47M
Day High
Day Low